Opioid Withdrawal Symptoms after Conversion to Oral Oxycodone/Naloxone in Advanced Cancer Patients Receiving Strong Opioids |
Kim, Jung Hoon
(Department of Hematology-Oncology, Gyeongsang National University Hospital, Gyeongsang National University School of Medicine)
Song, Haana (Department of Hematology-Oncology, Gyeongsang National University Hospital, Gyeongsang National University School of Medicine) Lee, Gyeong-Won (Department of Hematology-Oncology, Gyeongsang National University Hospital, Gyeongsang National University School of Medicine) Kang, Jung Hun (Department of Hematology-Oncology, Gyeongsang National University Hospital, Gyeongsang National University School of Medicine) |
1 | Lowenstein O, Leyendecker P, Hopp M, Schutter U, Rogers PD, Uhl R, et al. Combined prolonged-release oxycodone and naloxone improves bowel function in patients receiving opioids for moderate-to-severe non-malignant chronic pain: a randomised controlled trial. Expert Opin Pharmacother 2009;10:531-43. DOI |
2 | Rehni AK, Jaggi AS, Singh N. Opioid withdrawal syndrome: emerging concepts and novel therapeutic targets. CNS Neurol Disord Drug Targets 2013;12:112-25. DOI |
3 | Jung KW, Won YJ, Oh CM, Kong HJ, Lee DH, Lee KH. Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2014. Cancer Res Treat 2017;49:292-305. DOI |
4 | van den Beuken-van Everdingen MH, de Rijke JM, Kessels AG, Schouten HC, van Kleef M, Patijn J. Prevalence of pain in patients with cancer: a systematic review of the past 40 years. Ann Oncol 2007;18:1437-49. DOI |
5 | Bell T, Annunziata K, Leslie JB. Opioid-induced constipation negatively impacts pain management, productivity, and health-related quality of life: findings from the National Health and Wellness Survey. J Opioid Manag 2009;5:137-44. |
6 | Choi YS, Hong MH, Kim MJ. The role of opioid antagonists in constipation. Korean J Hosp Palliat Care 2001;4:113-21. |
7 | Pond SM, Tozer TN. First-pass elimination. Basic concepts and clinical consequences. Clin Pharmacokinet 1984;9:1-25. |
8 | Smith K, Hopp M, Mundin G, Bond S, Bailey P, Woodward J, et al. Low absolute bioavailability of oral naloxone in healthy subjects. Int J Clin Pharmacol Ther 2012;50:360-7. DOI |
9 | Liu M, Wittbrodt E. Low-dose oral naloxone reverses opioid-induced constipation and analgesia. J Pain Symptom Manage 2002;23:48-53. DOI |
10 | Leppert W. Role of oxycodone and oxycodone/naloxone in cancer pain management. Pharmacol Rep 2010;62:578-91. DOI |
11 | Kang JH, Lee GW, Shin SH, Bruera E. Opioid withdrawal syndrome after treatment with low-dose extended-release oxycodone and naloxone in a gastric cancer patient with portal vein thrombosis. J Pain Symptom Manage 2013;46:e15-7. DOI |
12 | Latasch L, Zimmermann M, Eberhardt B, Jurna I. Treament of morphine-induced constipation with oral naloxone. Anaesthesist 1997;46:191-4. DOI |
13 | Wilcock A. Prolonged-release naloxone can cause systemic opioid withdrawal. Eur J Pain 2009;13:1001; author reply 1002-3. DOI |
14 | Wong A, Macleod D, Robinson J, Koutsogiannis Z, Graudins A, Greene SL. Oxycodone/naloxone preparation can cause acute withdrawal symptoms when misused parenterally or taken orally. Clin Toxicol (Phila) 2015;53:815-8. DOI |
15 | Ahmedzai SH, Nauck F, Bar-Sela G, Bosse B, Leyendecker P, Hopp M. A randomized, double-blind, active-controlled, double-dummy, parallel-group study to determine the safety and efficacy of oxycodone/naloxone prolonged-release tablets in patients with moderate/severe, chronic cancer pain. Palliat Med 2012;26:50-60. DOI |